Diacomit Oral Susp

  • Seizure disorders

Diacomit Oral Susp Generic Name & Formulations

General Description

Stiripentol 250mg, 500mg; per packet; pwd for oral susp; fruit flavor; contains phenylalanine.

Pharmacological Class


See Also

How Supplied

Caps—60; Pkts—60


Generic Availability


Diacomit Oral Susp Indications


Treatment of seizures associated with Dravet syndrome in patients taking clobazam.

Diacomit Oral Susp Dosage and Administration

Adults and Children

<6mos or <7kg: not established. Swallow caps whole. Take with water and food. Oral susp: mix in water and drink immediately. ≥6mos–<1yr (≥7kg): 50mg/kg/day in 2 divided doses. ≥1yr (7–<10kg): 50mg/kg/day in 2 divided doses; (≥10kg): 50mg/kg/day in 2–3 divided doses. All: max 3000mg/day.

Diacomit Oral Susp Contraindications

Not Applicable

Diacomit Oral Susp Boxed Warnings

Not Applicable

Diacomit Oral Susp Warnings/Precautions


Monitor for somnolence; if occurs when concomitant clobazam, consider reducing initial clobazam by 25%; if persists, consider reducing by an additional 25%. Increased risk of suicidal thoughts or behavior; monitor for new or worsening depression, suicidal thoughts/behavior, and/or any unusual changes. Neutropenia. Thrombocytopenia. Obtain hematologic testing prior to initiation, then every 6 months. Monitor patient's weight during therapy; and the growth rate of pediatric patients. Phenylketonuria (oral susp). Moderate or severe renal/hepatic impairment: not recommended. Withdraw gradually. Avoid abrupt cessation. Elderly. Pregnancy. Nursing mothers.

Diacomit Oral Susp Pharmacokinetics

See Literature

Diacomit Oral Susp Interactions


May affect CYP1A2, CYP2B6, and CYP3A4 substrates (eg, theophylline, caffeine, sertraline, thiotepa, midazolam, triazolam, quinidine); consider dose adjustment. May potentiate CYP2C8, CYP2C19, P-gp, or BCRP substrates (eg, diazepam, clopidogrel, carbamazepine, methotrexate, prazosin, glyburide) and clobazam; consider dose reduction of these drugs. May be antagonized by strong CYP1A2, CY3A4 or CYP2C19 inducers (eg, rifampin, phenytoin, phenobarbital, carbamazepine); avoid or adjust dose. May increase risk of sedation and somnolence with concomitant other CNS depressants, alcohol.

Diacomit Oral Susp Adverse Reactions

Adverse Reactions

Somnolence, decreased appetite, agitation, ataxia, weight decreased, hypotonia, nausea, tremor, dysarthria, insomnia.

Diacomit Oral Susp Clinical Trials

See Literature

Diacomit Oral Susp Note


Enroll pregnant patients in the North American Antiepileptic Drug Pregnancy Registry by calling (888) 233-2334.

Diacomit Oral Susp Patient Counseling

See Literature